Bambusa Therapeutics, Inc. Filed Primary

What the company does

Bambusa Therapeutics is a clinical-stage biopharmaceutical company developing next-generation, long-acting precision bispecific antibodies for immunology and inflammation (I&I) diseases. Its lead product candidates are BBT001 and BBT002, and it has two preclinical candidates, BBT003 and BBT004. Its antibody platform originates from BioNTech Zhuhai.

Use of proceeds

We intend to use the net proceeds, together with existing cash, cash equivalents, and marketable securities, primarily to fund continued development of BBT001, including the initiation of a planned Phase 2b AD Study, and BBT002, including an expected Phase 2b trial in one respiratory indication. The remaining proceeds will fund research and development, including advancing BBT003 and BBT004 into clinical development, as well as capital expenditures, working capital, and general corporate purposes.

Underwriters

Extracted from S-1 0001628280-26-065557, filed Oct 9, 2026 and verified against that filing text.

Key risk factors

• Limited operating history

  “We have a limited operating history, which may make it difficult for you to evaluate our current business and predict our future success and viability.”

• Continued losses

  “Since our formation, we have incurred, and anticipate that we will continue to incur, significant losses and negative cash flows for the foreseeable future.”

• Going concern doubt

  “Our management has concluded that there is substantial doubt as to our ability to continue as a going concern. If we cannot continue as a going concern, our stockholders may lose some or all of their investment.”

• Clinical and regulatory risk

  “Clinical development is expensive, time consuming, and inherently unpredictable, and we are subject to regulatory requirements of multiple countries where we are conducting clinical trials.”

• Dependence on product candidates

  “Our business depends entirely on the success of our product candidates, and we cannot guarantee that we will successfully complete clinical development, receive regulatory approval, or successfully commercialize any or all of our current or future product candidates.”

• Competition

  “We face substantial competition, including from other biotechnology and pharmaceutical companies, who may discover, develop, or commercialize therapies before or more successfully than we do.”

• Future capital needs and dilution

  “Even if this offering is successful, we will require substantial additional capital to finance our operations, which may cause dilution to our stockholders, restrict our operations, or require us to relinquish rights to our technologies or current or future product candidates.”

• Preferred stock issuance

  “The powers, preferences, and rights of these additional series of convertible preferred stock may be senior to or on parity with our common stock, which may reduce our common stock’s value.”